Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer

Added 55 days ago (17.06.2022)

Authors: Meiyu Wu; Shuxia Qin; Liting Wang; Chongqing Tan; Ye Peng; Xiaohui Zeng; Xia Luo; Lidan Yi; Xiaomin Wan